Biocon has partnered with Brazil-based Biomm SA for the commercialization of its diabetes drug, Semaglutide (gOzempic). Biocon will develop, manufacture, and supply the drug, while Biomm will obtain regulatory approval and commercialization in Brazil. Biomm focuses on developing, manufacturing, and commercialising complex biotech and biosimilar drug products.
